Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics

Treating periodontitis with metronidazole (MET) as an adjunct to scaling root planing (SRP) is suggested to have inconsistent effects on insulin resistance (IR) in type 2 diabetes mellitus (T2DM). This paper will present the effects of MET, in addition to SRP, on the homeostatis model assessment of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ambrina Qureshi, Zeba Haque, Hina Qureshi, Waqas Ahmed Farooqui
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/ba11145ec4eb4771a3e1f5d5b2667488
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ba11145ec4eb4771a3e1f5d5b2667488
record_format dspace
spelling oai:doaj.org-article:ba11145ec4eb4771a3e1f5d5b26674882021-11-25T16:24:46ZEffects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics10.3390/antibiotics101114002079-6382https://doaj.org/article/ba11145ec4eb4771a3e1f5d5b26674882021-11-01T00:00:00Zhttps://www.mdpi.com/2079-6382/10/11/1400https://doaj.org/toc/2079-6382Treating periodontitis with metronidazole (MET) as an adjunct to scaling root planing (SRP) is suggested to have inconsistent effects on insulin resistance (IR) in type 2 diabetes mellitus (T2DM). This paper will present the effects of MET, in addition to SRP, on the homeostatis model assessment of IR (HOMA-IR). A three-arm clinical trial was conducted and analyses were performed on T2DM participants with periodontitis (<i>n</i> = 74) who completed follow-up visits at 3 and 6 months after the intervention. The observed between-group and within-group mean changes in IR were found using ANOVA with repeated measures, followed by a post-hoc analysis, and a <i>p</i>-value of ≤0.05 was considered significant. Between-group analyses showed no difference in the HOMA-IR at 3 months, but at 6 months the difference was significant (<i>p</i> = 0.046). Within-group analyses showed that the HOMA-IR was significantly reduced in both test groups (<i>p</i> ≤ 0.05) over the period of time. Adjunct use of MET may result in a sudden short-term lowering of the HOMA-IR level within 3 months that may not be retained over 6 months when compared to the sustained lowering of the HOMA-IR levels in T2DM when intervened with SRP without MET.Ambrina QureshiZeba HaqueHina QureshiWaqas Ahmed FarooquiMDPI AGarticlenon-surgical periodontal therapyinsulin resistanceantibioticstype 2 diabetes mellitusclinical trialTherapeutics. PharmacologyRM1-950ENAntibiotics, Vol 10, Iss 1400, p 1400 (2021)
institution DOAJ
collection DOAJ
language EN
topic non-surgical periodontal therapy
insulin resistance
antibiotics
type 2 diabetes mellitus
clinical trial
Therapeutics. Pharmacology
RM1-950
spellingShingle non-surgical periodontal therapy
insulin resistance
antibiotics
type 2 diabetes mellitus
clinical trial
Therapeutics. Pharmacology
RM1-950
Ambrina Qureshi
Zeba Haque
Hina Qureshi
Waqas Ahmed Farooqui
Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
description Treating periodontitis with metronidazole (MET) as an adjunct to scaling root planing (SRP) is suggested to have inconsistent effects on insulin resistance (IR) in type 2 diabetes mellitus (T2DM). This paper will present the effects of MET, in addition to SRP, on the homeostatis model assessment of IR (HOMA-IR). A three-arm clinical trial was conducted and analyses were performed on T2DM participants with periodontitis (<i>n</i> = 74) who completed follow-up visits at 3 and 6 months after the intervention. The observed between-group and within-group mean changes in IR were found using ANOVA with repeated measures, followed by a post-hoc analysis, and a <i>p</i>-value of ≤0.05 was considered significant. Between-group analyses showed no difference in the HOMA-IR at 3 months, but at 6 months the difference was significant (<i>p</i> = 0.046). Within-group analyses showed that the HOMA-IR was significantly reduced in both test groups (<i>p</i> ≤ 0.05) over the period of time. Adjunct use of MET may result in a sudden short-term lowering of the HOMA-IR level within 3 months that may not be retained over 6 months when compared to the sustained lowering of the HOMA-IR levels in T2DM when intervened with SRP without MET.
format article
author Ambrina Qureshi
Zeba Haque
Hina Qureshi
Waqas Ahmed Farooqui
author_facet Ambrina Qureshi
Zeba Haque
Hina Qureshi
Waqas Ahmed Farooqui
author_sort Ambrina Qureshi
title Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
title_short Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
title_full Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
title_fullStr Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
title_full_unstemmed Effects of Metronidazole as an Adjunct to Non-Surgical Periodontal Therapy on Insulin Resistance in Type 2 Diabetics
title_sort effects of metronidazole as an adjunct to non-surgical periodontal therapy on insulin resistance in type 2 diabetics
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/ba11145ec4eb4771a3e1f5d5b2667488
work_keys_str_mv AT ambrinaqureshi effectsofmetronidazoleasanadjuncttononsurgicalperiodontaltherapyoninsulinresistanceintype2diabetics
AT zebahaque effectsofmetronidazoleasanadjuncttononsurgicalperiodontaltherapyoninsulinresistanceintype2diabetics
AT hinaqureshi effectsofmetronidazoleasanadjuncttononsurgicalperiodontaltherapyoninsulinresistanceintype2diabetics
AT waqasahmedfarooqui effectsofmetronidazoleasanadjuncttononsurgicalperiodontaltherapyoninsulinresistanceintype2diabetics
_version_ 1718413222761988096